{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-024061","form_type":"8-K","ticker":"BTCY","cik":"0001630113","company_name":"BIOTRICITY INC.","filed_at":"2025-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.983974+00:00","generated_at":"2026-05-16T18:48:15.596525+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biotricity Q2 FY2026 revenue up 19% to $3.9M; net loss narrows 53% to $0.77M","bullets":["Revenue $3.9M (+19% YoY); gross margin 81.9% vs 75.3% prior year.","Net loss $0.77M ($0.03/sh) vs $1.7M ($0.07/sh), a 53% improvement.","Recurring TaaS technology fees $3.5M, 88.7% of total revenue.","Regulatory progress in Canada, Saudi Arabia, and Argentina; GPOs covering 90% of U.S. hospitals.","CEO cites AI-driven automation and Biocore Pro adoption as growth drivers."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-024061","json":"https://secwatch.observer/filing/0001493152-25-024061.json","markdown":"https://secwatch.observer/filing/0001493152-25-024061.md","text":"https://secwatch.observer/filing/0001493152-25-024061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630113/000149315225024061/0001493152-25-024061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630113/000149315225024061/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T18:48:15.596525+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}